Platelet function testing and cardiovascular outcomes: Steps forward in identifying the best predictive measure

Thrombosis and Haemostasis

Volumn 98, Issue 4, 2007, Pages 707-709

  Angiolillo, Dominick J ^a   Alfonso, Fernando ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PURINE P2Y12 RECEPTOR; PYRIDINE DERIVATIVE; THROMBIN RECEPTOR; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ACUTE CORONARY SYNDROME; ASSAY; CARDIOVASCULAR DISEASE; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DRUG EFFICACY; DRUG RESPONSE; EDITORIAL; FLOW CYTOMETRY; FUNCTION TEST; HIGH RISK PATIENT; HUMAN; LOADING DRUG DOSE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS;

ADENOSINE DIPHOSPHATE; CARDIOVASCULAR DISEASES; FLOW CYTOMETRY; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PYRIDINES; ROC CURVE; SENSITIVITY AND SPECIFICITY; TICLOPIDINE; TREATMENT OUTCOME;

EID: 35048825671     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-08-0518     Document Type: Editorial

References (18)

1. Angiolillo DJ, Fernandez-Ortix A, Bernanrdo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management and future perspectives. J Am Coll Cardiol 2007; 49: 1505-1516.
2. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006; 47: e1-121.
3. Yusuf S, Zhao F, Mehta SR, et al.; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
4. Steinhubl SR, Berger PB, Mann JT 3rd, et al. CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial (CREDO). J Am Med Assoc 2002; 288: 2411-2420.
5. Sabatine MS, Cannon CP, Gibson CM, et al; Clopidogrel as Adjunctive Reperftision Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. CLARITY-TIMI 28 Investigators. N Engl J Med 2005; 352: 1179-1189.
6. Chen ZM, Jiang LX, Chen YP et al; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607-1621.
7. Frere C, Cuisset T, Quilici J, et al. Determination of prognostic values of ADP-induced platelet aggregation and platelet reactivity index VASP for clinical out-comes in non-ST elevation acute coronary syndrome. Thromb Haemost 2007; 98: 838-843.
8. Cattaneo M. Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection. J Thromb Haemost 2007; 5 (Suppl 1): 230-237.
9. Angiolillo DJ. ADP receptor antagonism: What's in the pipeline? Am J Cardiovasc Drugs 2007; in press.
10. Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005; 46: 1820-1826.
11. Angiolillo DJ, Bernardo E, Ramirez C, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2007; in press.
12. Hochholzer W Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48: 1742-1750.
13. Cuisset T, Frere C, Quilici J, et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006; 4: 542-549.
14. Cuisset T, Frere C, Quilici J, et al. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. Thromb Haemost 2007; 97: 282-287.
15. Cuisset T, Frere C, Quilici J, et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 2006; 48: 1339-1345.
16. Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 49: 2312-2317.
17. Alfonso F, Angiolillo DJ. Platelet function assessment to predict outcomes after coronary interventions: hype or hope? J Am Coll Cardiol 2006; 48: 1751-1754.
18. Angiolillo DJ, Shoemaker SB, Desai B, et al. A randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease. Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study. Circulation 2007; 115: 708-716.